GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma

Phase 2

Withdrawn

Conditions: Sarcoma, Soft Tissue

Interventions: Drug: Pazopanib 800 mg
Drug: Placebo

First Posted Date: 2015-02-20

Last Posted Date: 2016-10-12

Lead Sponsor: GlaxoSmithKline

Registration Number: NCT02367651

Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women

Phase 2

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: RSV vaccine GSK3003898A (formulation 2)
Biological: RSV vaccine GSK3003895A (formulation 1)
Biological: RSV vaccine GSK3003899A (formulation 3)
Biological: Boostrix

First Posted Date: 2015-02-10

Last Posted Date: 2018-07-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 507

Registration Number: NCT02360475

Locations: 🇩🇪
GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany

A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques

Phase 1

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Other: Gadobutrol
Other: 18F-FDG
Other: 18F-GE-180

First Posted Date: 2015-01-29

Last Posted Date: 2017-12-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10

Registration Number: NCT02350426

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects

Phase 1

Completed

Conditions: Anaemia

Interventions: Drug: GSK1278863A Placebo
Drug: GSK1278863A

First Posted Date: 2015-01-28

Last Posted Date: 2017-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 34

Registration Number: NCT02348372

Locations: 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia

Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors

Phase 1

Completed

Conditions: Cancer
Neoplasms

Interventions: Drug: GSK2849330
Drug: 89Zr-GSK2849330

First Posted Date: 2015-01-26

Last Posted Date: 2019-02-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT02345174

Locations: 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands

fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplementation of Bacopa Monnieri Extract and Multiple Micronutrient Supplementation.

Not Applicable

Completed

Conditions: Growth and Development

Interventions: Dietary Supplement: Non-fortified isocaloric beverage powder
Dietary Supplement: Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation

First Posted Date: 2015-01-26

Last Posted Date: 2015-04-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 80

Registration Number: NCT02345187

Locations: 🇮🇳
GSK Investigational Site, New Delhi, India

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Budesonide/Formoterol
Drug: Triple FF/UMEC/VI
Drug: Placebo to match FF/UMEC/VI
Drug: Placebo to match Budesonide/Formoterol combination
Drug: Albuterol/salbutamol